Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

OBJECTIVE:To investigate the effects of clopidogrel plus atorvastatin on ischemic cardiovascular diseases and to explore the clinical significance of drug interactions.METHODS:Literatures were retreived from EMBase,PubMed,Cochrane Library and CNKI with clopidogrel,atorvastatin,clinical trial as

Anemia, Aplastic ; prevention & control ; therapy ; Humans

Autophagy is a classical regulatory mechanism of energy metabolism and self-update system in the maintenance of the intracellular homeostasis and cell development. Autophagy has been recently found to play a role in tumor development. Autophagy regulates tumor formation, proliferation, metastasis, and metabolism. At the same time, the anticancer drugs formed with autophagic mediators have been used in the treatment, which suggested that improving autophagy activity to inhibit tumor has become a new way for cancer treatment of cancer patients. This article gives an overview of the regulatory mechanism of autophagy, the relationship between autophagy and tumor, and tumor therapy by targeting autophagy.
Antineoplastic Agents ; Autophagy ; Humans ; Neoplasms ; physiopathology

Hemoglobinuria, Paroxysmal ; metabolism ; Humans ; Membrane Proteins ; biosynthesis

Humans ; Membrane Proteins ; metabolism ; Myelodysplastic Syndromes ; metabolism ; Receptors, Colony-Stimulating Factor ; metabolism ; Signal Transduction

Objective To explore the relationship between serum advanced glycation end products(AGEs) levels in gestation diabetic mother(GDM) and cardiovascular function of newborn infants.Methods Sixty mid-gestation GDM and 72 late-gestation GDM fulfilling the inclusion criteria were recruited,72 mid-gestation and 80 late-gestation mothers with no pregnancy complications were collected as controls.Fasting blood glucose and serum AGEs levels were analyzed in each group.Clinical data of GDM and their babys were collected.Accor-ding to cardiovascular function of neonates,these neonates were divided into 2 groups:normal neonate group with normal cardiovascular function and anormal neonate group with anormal cardiovascular function.Maternal serum AGEs levels,blood glucose between mid-gestation groups and late-gestation groups were compared.Factors which affected the prevalence of complications of fetal outcome in GDM were analyzed.Results 1.Mid-gestation and late-gestation GDM groups had higher serum AGEs levels and fasting blood glucose compared with those of their respective controls(Pa0.05).3.Abnormal fetal outcome in GDM had significantly higher maternal serum AGEs levels than that in controls with normal fetal outcome(P

Dyslipidemia is a well-established risk factor for atherosclerosis. Treating dyslipidemia in elderly patients requires specific knowledge and understanding of common dyslipidemias and the relative safety of various pharmacologic agents in the presence of possible multiple comorbidities. Lifestyle modification remains the first step in the treatment of dyslipidemia; however, it can be difficult to sustain and achieve acceptable compliance in the elderly and it is best used in combination with drug therapy. Statins are widely accepted as the first-line therapy. Several recent studies have demonstrated that statins are safe and effective in the elderly. However, it is important to note that there is very limited data regarding the effects of dyslipidemia treatment on morbidity and mortality in patients over 85 years of age. In summary, the clinicians must recognize that the presence of dyslipidemia in the elderly poses substantial risk of coronary events and stroke. The available evidence has demonstrated that in most elderly patients who are at increased risk for cardiovascular morbidity and mortality, treatment of dyslipidemia with appropriate therapy reduces the risk, and when used carefully with close monitoring for safety, the treatment is generally well tolerated. With increasing life expectancy, it is critical for physicians to recognize the importance of detection and treatment of dyslipidemia in the elderly.

Objective:To establish a method for determining the immunological activity of ribonucleic acid. Methods: Leucocyte adherence inhibition test ( LAI) was applied, and the important parameters of LAI including the mouse strain, drug concentration, treatment time, content of buffer solution and cell density were researched. The immunological activity of RNAⅠ, Ⅱand Ⅲ was re-spectively determined by the method. Results:Stable and reliable parameters were obtained: the sample concentration was 10 mg· ml-1 , the treatment time was 2 hours, Ca2+ and Mg2+ were necessary for the buffer solution, and the cell density was about 4 × 107 cell·ml-1 . The strain of mouse showed no effect on the results. As a result, the determination method for immunological activity was established. Using the method, the immunological activity of RNA Ⅰ,Ⅱand Ⅲ was determined 3 times, and the results met the re-quirements with RSD below 20%. Conclusion:The method is suitable for determining the immunological activity of RNA.

Aim To investigate the relationship be-tween phosphoprotein EBP50 and the proliferation of breast cancer in MCF-7 cells. Methods The quali-fied recombinant plasmid sh-EBP50-pGPU6/Neo was transfected into MCF-7 cells with EBP50 knocking down. The expression of EBP50, c-myc, p-ERK1/2, and ERK1/2 was detected by Western blot. The prolif-eration ability of cells was detected by sulforhodamine B assay. Results The EBP50 knocking down plasmid was constructed successfully. MCF-7 cells with EBP50 knocking down had been established successfully. Knocking down of EBP50 increased the proliferation of MCF-7 significantly, and partially augmented the ex-pression of c-myc and phosphorylation of ERK1/2 . However, knocking down of EBP50 did not impact the expression of ERK1/2 . Conclusion EBP50 suppres-ses the proliferation of breast cancer cell through inhib-iting the activity of ERK1/2 in MCF-7 cell line.